July 06, 2001 / 12:00 am, CEST
MorphoSys AG (Neuer Markt: MOR) announced today that at its annual shareholder meeting yesterday, the Company's shareholders confirmed the appointment of Dr. Jörg Reinhardt to the MorphoSys supervisory board. In his current position as Director of Pharmaceutical Development and member of the Executive Committee at Novartis Pharma, Dr. Reinhardt is responsible for worldwide pre-clinical and clinical drug development, clinical pharmacology, regulatory affairs and project management.
"Dr. Reinhardt' s extensive knowledge in product development will play an important role at MorphoSys as we build our own internal product pipeline," commented Dr. Simon Moroney, MorphoSys AG. "We look forward to working with him and are sure he will complement the existing experience on our board."
In addition to the confirmation of Dr. Reinhardt's appointment to the supervisory board, all other management proposals of the shareholder assembly agenda were passed at the meeting, which took place in Planegg/Munich, Germany.
MorphoSys develops and applies innovative technologies for the production of synthetic antibodies, which accelerate drug discovery and target characterization. Founded in 1992, the Company's proprietary Human Combinatorial Antibody Library (HuCAL®) technology is used by researchers world-wide for human antibody generation. The Company currently has licensing and research collaborations with Bayer (Berkeley, California/USA), Biogen (Cambridge, Massachusetts/USA), Centocor (Malvern, PA/USA), Chiron (Emeryville, California/USA), DuPont Pharmaceuticals (Wilmington, Delaware/USA), Eos Biotechnology (South San Francisco/California/USA), GPC Biotech AG (Munich/Germany), Hoffmann-La Roche AG (Basel/Switzerland), ImmunoGen (Cambridge, Massachusetts/USA), Millennium (Cambridge, Mass/USA) and ProChon Biotech (Revohot/Israel).
Statements included in this press release which are not historical in nature are intended to be, and are hereby identified as, “forward-looking statements” for purposes of the safe harbour provided by Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words including “anticipates”, “believes”, “intends”, “estimates”, “expects” and similar expressions. The company cautions readers that forward-looking statements, including without limitation those relating to the company’s future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Factors that may affect future operations and business prospects include, but are not limited to, clinical and scientific results and developments concerning corporate collaborations and the company’s proprietary rights and other factors described in the prospectus relating to the company’s recent public offering.
For further information, please contact:
Chief Financial Officer
Tel.: +49 (0) 89 / 899 27-439
Fax: +49 (0) 89 / 899 27-5309
Dr. Claudia Gutjahr-Löser
Manager Corporate Communications
Tel.: +49 (0) 89 / 899 27-122
Fax: +49 (0) 89 / 899 27-5122